Daré Bioscience (DARE)
Develops women's-health products spanning contraception, sexual health, menopause and vaginal health.
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.45 per share a year ago.
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review its financial results for the quarter ended June 30, 2026 and to provide a company update.
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré's strategy to build a trusted women's health ecosystem spanning products, education and access to care
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative designed to provide shareholders with direct access to the Company's leadership and the opportunity to learn more about Daré's commercial strategy, product portfolio, growth opportunities and long-term vision. Hosted by President and Chief Executive Officer, Sabrina Martucci Johnson, the live webinar series will feature corporate presentations, discussions surrounding the Company's women's health portfolio and commercialization strategy, updates on key business initiatives, and interactive question-and-answer sessions with investors.
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Live video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET.
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Live video webcast on Tuesday, July 14 th , at 4:00 PM ET Register here
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
First consumer health product positions Daré for revenue generation while expanding its women's health leadership platform
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trial DARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in the U.S., for which there are currently no FDA-approved pharmacologic treatments Award reflects Daré's strategy of leveraging non-dilutive government funding, including both NIH grants and ARPA-H contract support for DARE-HPV, to advance a differentiated pipeline addressing some of the most persistent unmet needs in women's health SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced receipt of a Notice of Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), obligating the second and final tranche of $1.0 million under the previously announced up to $2.0 million NIAID grant award for DARE-HPV, Daré's investigational treatment for persistent high-risk human papillomavirus (HPV) infection. The total amount of the award across the project period, which commenced in late 2024, is $2.0 million.
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed to evaluate DARE-HPV as a potential treatment for persistent high-risk human papillomavirus (HPV) infection. DARE-HPV is being developed as a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infection.
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week.
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free contraceptive.